Replies to post #115778 on Biotech Values

[DewDiligence]

I was surprised yesterday to see a report yesterday that Gilenia is taking very few Tysabri patients.

There are not that many Tysabri patients to be taken: #msg-56125835.

[ciotera]

Isn't Tysabri limited to the most severe later line patients as a treatment of "last resort"? I'm not surprised that it's not affected by Gilenya as much as the first line treatments. My guess would be that it would steal most patients from Avonex.